<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020196.anc" start="1829" end="1835" sStart="1716" offset="113" sid="r11.strong.j.0983" wn="2" wnkey="strong%5:00:00:intense:00" text="Early attempts to develop a Lassa fever vaccine in the 1980s focused on killed pathogens, which caused a strong humoral response but failed to protect nonhuman primate test animals." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020196.anc" start="395" end="401" sStart="null" offset="114" sid="null" wn="6" wnkey="severe%5:00:01:bad:00" text="The disease is asymptomatic or mild in approximately 80% of infected patients, but the remaining 20% have severe multisystem disease." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020196.anc" start="395" end="401" sStart="null" offset="114" sid="null" wn="5" wnkey="severe%5:00:00:critical:03" text="The disease is asymptomatic or mild in approximately 80% of infected patients, but the remaining 20% have severe multisystem disease." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020196.anc" start="395" end="401" sStart="null" offset="114" sid="r11.severe.j.0662" wn="5" wnkey="severe%5:00:00:critical:03" text="The disease is asymptomatic or mild in approximately 80% of infected patients, but the remaining 20% have severe multisystem disease." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020196.anc" start="950" end="956" sStart="null" offset="111" sid="r11.severe.j.0052" wn="1" wnkey="severe%5:00:00:intense:00" text="Disease severity does not seem to affect this complication: deafness may develop in mild as well as in severe cases." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020196.anc" start="395" end="401" sStart="null" offset="114" sid="null" wn="1" wnkey="severe%5:00:00:intense:00" text="The disease is asymptomatic or mild in approximately 80% of infected patients, but the remaining 20% have severe multisystem disease." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020196.anc" start="950" end="956" sStart="null" offset="111" sid="r11.severe.j.0052" wn="6" wnkey="severe%5:00:01:bad:00" text="Disease severity does not seem to affect this complication: deafness may develop in mild as well as in severe cases." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020196.anc" start="1788" end="1794" sStart="null" offset="72" sid="r9.kill.v.0611" wn="10" wnkey="kill%2:35:01::" text="Early attempts to develop a Lassa fever vaccine in the 1980s focused on killed pathogens, which caused a strong humoral response but failed to protect nonhuman primate test animals." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020196.anc" start="2937" end="2944" sStart="null" offset="168" sid="r10.control.n.0805" wn="4" wnkey="control%1:09:02::" text="A single intramuscular vaccination protected all four vaccinated cynomolgus macaques against a lethal challenge of a particular Lassa strain, while two control monkeys that had received empty vector died after injection with the same dose of virus." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020196.anc" start="659" end="665" sStart="null" offset="9" sid="r10.common.j.0613" wn="4" wnkey="common%5:00:00:familiar:02" text="The most common complication of Lassa fever is deafness." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020196.anc" start="1998" end="2010" sStart="null" offset="84" sid="r11.combination.n.0960" wn="1" wnkey="combination%1:14:00::" text="Subsequently, recombinant vaccines used vaccinia vectors carrying different combinations of structural Lassa proteins." />
    <s path="[OANC]/data/written_2/technical/plos/pmed.0020196.anc" start="2129" end="2136" sStart="null" offset="88" sid="r11.absence.n.0767" wn="1" wnkey="absence%1:26:00::" text="Some of these protected 90% of nonhuman primates from a lethal challenge in the absence of a strong humoral response, suggesting that cellular responses are important for protection." />
  </sentences>
</list>